{"id":8406,"date":"2019-10-25T22:00:18","date_gmt":"2019-10-26T02:00:18","guid":{"rendered":"https:\/\/mutualisation.ca\/en\/?p=8406"},"modified":"2022-04-27T10:08:32","modified_gmt":"2022-04-27T14:08:32","slug":"drug-monitoring-a-quick-look-at-new-drugs-and-new-trends","status":"publish","type":"post","link":"https:\/\/staging.mutualisation.ca\/en\/2019\/10\/25\/drug-monitoring-a-quick-look-at-new-drugs-and-new-trends\/","title":{"rendered":"Drug monitoring: a quick look at new drugs and new trends"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"8406\" class=\"elementor elementor-8406 elementor-4092\" data-elementor-post-type=\"post\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-778c7881 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"778c7881\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-48a7b281\" data-id=\"48a7b281\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-1b59df19 elementor-widget elementor-widget-text-editor\" data-id=\"1b59df19\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><strong>October 2019<\/strong> \u2013 Rising drug costs are a constant concern for the Corporation, which makes sure that the pooling system continues to protect plan viability in case of major claims.\u00a0<\/p><p><img fetchpriority=\"high\" decoding=\"async\" class=\"alignright wp-image-6126\" src=\"https:\/\/staging.mutualisation.ca\/wp-content\/uploads\/2016\/04\/bg-footer-04-1-1-1024x769.jpg\" alt=\"mol\u00e9cules\" width=\"400\" height=\"300\" srcset=\"https:\/\/staging.mutualisation.ca\/wp-content\/uploads\/2016\/04\/bg-footer-04-1-1-1024x769.jpg 1024w, https:\/\/staging.mutualisation.ca\/wp-content\/uploads\/2016\/04\/bg-footer-04-1-1-300x225.jpg 300w, https:\/\/staging.mutualisation.ca\/wp-content\/uploads\/2016\/04\/bg-footer-04-1-1-768x576.jpg 768w, https:\/\/staging.mutualisation.ca\/wp-content\/uploads\/2016\/04\/bg-footer-04-1-1-22x17.jpg 22w, https:\/\/staging.mutualisation.ca\/wp-content\/uploads\/2016\/04\/bg-footer-04-1-1-800x600.jpg 800w, https:\/\/staging.mutualisation.ca\/wp-content\/uploads\/2016\/04\/bg-footer-04-1-1-1200x901.jpg 1200w, https:\/\/staging.mutualisation.ca\/wp-content\/uploads\/2016\/04\/bg-footer-04-1-1.jpg 1920w\" sizes=\"(max-width: 400px) 100vw, 400px\" \/>In 2011, the Corporation began monitoring new drugs and costs related to their use. This tool allows it to anticipate the level of financial risk that insured and uninsured plans will be exposed to. The Corporation relies on information obtained from monitoring to revise the pooling system\u2019s thresholds and annual factors based on market needs.<\/p><p>The Corporation also monitors drugs rejected by the INESSS. Although these drugs are rejected when they do not meet the Institute\u2019s therapeutic value criteria, they are sometimes eligible under the exception patient category and may also be reimbursed by private plans.<\/p><p>The Corporation\u2019s monitoring efforts mainly target costly new drugs that may be approved and prescribed to fight cancer, rare (genetic) diseases and other conditions.<\/p><h4><strong>Drugs being monitored<\/strong><\/h4><p>The Corporation monitors drugs whose estimated annual cost is over $45,000 and that could have a significant impact on private plans. Among these, 58 new drugs were analyzed in 2018, including 32 for cancer, 18 for rare diseases, 1 for Hepatitis C and 7 for other diseases.<\/p><p>Special attention is paid to new drugs for rare (genetic) diseases, which are often very expensive. Also, such diseases may affect more than one member of a single family, which inflates an insured person\u2019s cost per certificate.<\/p><p>The Corporation also monitored 25 drugs with estimated costs between $15,000 and $45,000.<\/p><h4><strong>Trends for 2020<\/strong><\/h4><p>Based on the information obtained, over the course of the last two years, we observed stability in terms of inflation factors for pooled claims below $200,000.<\/p><p>For the coming years, the reduction in the price of generic drugs, the use of biosimilars, the decrease in the cost of Hepatitis C treatments and new PMPRB (Patented Medicine Prices Review Board) regulations will have a downward impact on inflation factors. However, the accelerated rate at which the INESSS is studying new drugs and the substantial increase in the number of new drugs expected to enter the market in the years to come will have an upward impact.<\/p><p>Among the expensive new drugs most likely to have an impact on pooling are Crysvita, Vitrakvi, Vizimpro, Radicava and Translarna.<\/p><p>If it materializes, the Canadian government\u2019s national prescription drug coverage plan could also have an impact in the longer term.<\/p><h4><strong>Monitoring through surveys<\/strong><\/h4><p>Every year, as part of its annual consultations, the Corporation conducts a survey of its participants on reimbursed drugs valued at over $200,000.<\/p><p><img decoding=\"async\" class=\"alignleft wp-image-19435\" src=\"https:\/\/staging.mutualisation.ca\/wp-content\/uploads\/2022\/02\/pexels-karolina-grabowska-4021819-300x200.jpg\" alt=\"Vigie m\u00e9dicaments\" width=\"400\" height=\"267\" srcset=\"https:\/\/staging.mutualisation.ca\/wp-content\/uploads\/2022\/02\/pexels-karolina-grabowska-4021819-300x200.jpg 300w, https:\/\/staging.mutualisation.ca\/wp-content\/uploads\/2022\/02\/pexels-karolina-grabowska-4021819-1024x683.jpg 1024w, https:\/\/staging.mutualisation.ca\/wp-content\/uploads\/2022\/02\/pexels-karolina-grabowska-4021819-768x512.jpg 768w, https:\/\/staging.mutualisation.ca\/wp-content\/uploads\/2022\/02\/pexels-karolina-grabowska-4021819-1536x1024.jpg 1536w, https:\/\/staging.mutualisation.ca\/wp-content\/uploads\/2022\/02\/pexels-karolina-grabowska-4021819-2048x1365.jpg 2048w\" sizes=\"(max-width: 400px) 100vw, 400px\" \/>The main purpose of this initiative is to validate the information obtained through drug monitoring. The survey also reveals new practices not identified through monitoring.<\/p><p>Among other things, this monitoring via a survey identifies changes in government programs and transfers of treatments from hospitals to private clinics. It revealed that Cerdelga (Gaucher disease) and Galafold (Fabry disease) were reimbursed by the private sector; prior to this, these two drugs had been distributed free of charge through a government program. It was also revealed that the private sector\u2019s reimbursement of Spinraza, an exception drug, included on the RAMQ\u2019s List of Medications \u2014 Institutions, usually given under anaesthesia in hospital settings and given under anaesthesia, was administered in private clinics. These new trends will receive special monitoring, as they could have a significant impact on the volume of pooled claims.<\/p><p>Survey results indicate that:<\/p><ul><li>Currently, SOLIRIS is the drug with the highest number of pooled claims, accounting alone for more than 10% of pooling.<\/li><li>Currently, VIMIZIM is the most expensive drug in the pooling. The highest claim was on the order of $1.9M.<\/li><li>ORKAMBI is the expensive drug experiencing the most growth at this time. In the 2017 survey, we had reported 7 claims for a total reimbursement of $1.9M and the 2019 survey showed 22 claims for a total of $6.1M.<\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>The increasing cost of drugs is a constant concern for the Corporation, which ensures that the pooling system continues to protect the viability of plans in case of major claims.<\/p>\n","protected":false},"author":22,"featured_media":5500,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[542],"tags":[],"class_list":["post-8406","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-archives-fr"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Drug monitoring: a quick look at new drugs and new trends - SOCI\u00c9T\u00c9 DE COMPENSATION EN ASSURANCE M\u00c9DICAMENTS DU QU\u00c9BEC<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/staging.mutualisation.ca\/en\/2019\/10\/25\/drug-monitoring-a-quick-look-at-new-drugs-and-new-trends\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Drug monitoring: a quick look at new drugs and new trends - SOCI\u00c9T\u00c9 DE COMPENSATION EN ASSURANCE M\u00c9DICAMENTS DU QU\u00c9BEC\" \/>\n<meta property=\"og:description\" content=\"The increasing cost of drugs is a constant concern for the Corporation, which ensures that the pooling system continues to protect the viability of plans in case of major claims.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/staging.mutualisation.ca\/en\/2019\/10\/25\/drug-monitoring-a-quick-look-at-new-drugs-and-new-trends\/\" \/>\n<meta property=\"og:site_name\" content=\"SOCI\u00c9T\u00c9 DE COMPENSATION EN ASSURANCE M\u00c9DICAMENTS DU QU\u00c9BEC\" \/>\n<meta property=\"article:published_time\" content=\"2019-10-26T02:00:18+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-04-27T14:08:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/staging.mutualisation.ca\/wp-content\/uploads\/2016\/04\/header-2.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"878\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Andr\u00e9 Ouellette\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Andr\u00e9 Ouellette\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/staging.mutualisation.ca\\\/en\\\/2019\\\/10\\\/25\\\/drug-monitoring-a-quick-look-at-new-drugs-and-new-trends\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/staging.mutualisation.ca\\\/en\\\/2019\\\/10\\\/25\\\/drug-monitoring-a-quick-look-at-new-drugs-and-new-trends\\\/\"},\"author\":{\"name\":\"Andr\u00e9 Ouellette\",\"@id\":\"https:\\\/\\\/staging.mutualisation.ca\\\/#\\\/schema\\\/person\\\/16c02f97060cefce556dbfa34014498d\"},\"headline\":\"Drug monitoring: a quick look at new drugs and new trends\",\"datePublished\":\"2019-10-26T02:00:18+00:00\",\"dateModified\":\"2022-04-27T14:08:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/staging.mutualisation.ca\\\/en\\\/2019\\\/10\\\/25\\\/drug-monitoring-a-quick-look-at-new-drugs-and-new-trends\\\/\"},\"wordCount\":640,\"publisher\":{\"@id\":\"https:\\\/\\\/staging.mutualisation.ca\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/staging.mutualisation.ca\\\/en\\\/2019\\\/10\\\/25\\\/drug-monitoring-a-quick-look-at-new-drugs-and-new-trends\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/staging.mutualisation.ca\\\/wp-content\\\/uploads\\\/2016\\\/04\\\/header-2.jpg\",\"articleSection\":[\"Archives\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/staging.mutualisation.ca\\\/en\\\/2019\\\/10\\\/25\\\/drug-monitoring-a-quick-look-at-new-drugs-and-new-trends\\\/\",\"url\":\"https:\\\/\\\/staging.mutualisation.ca\\\/en\\\/2019\\\/10\\\/25\\\/drug-monitoring-a-quick-look-at-new-drugs-and-new-trends\\\/\",\"name\":\"Drug monitoring: a quick look at new drugs and new trends - SOCI\u00c9T\u00c9 DE COMPENSATION EN ASSURANCE M\u00c9DICAMENTS DU QU\u00c9BEC\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/staging.mutualisation.ca\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/staging.mutualisation.ca\\\/en\\\/2019\\\/10\\\/25\\\/drug-monitoring-a-quick-look-at-new-drugs-and-new-trends\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/staging.mutualisation.ca\\\/en\\\/2019\\\/10\\\/25\\\/drug-monitoring-a-quick-look-at-new-drugs-and-new-trends\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/staging.mutualisation.ca\\\/wp-content\\\/uploads\\\/2016\\\/04\\\/header-2.jpg\",\"datePublished\":\"2019-10-26T02:00:18+00:00\",\"dateModified\":\"2022-04-27T14:08:32+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/staging.mutualisation.ca\\\/en\\\/2019\\\/10\\\/25\\\/drug-monitoring-a-quick-look-at-new-drugs-and-new-trends\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/staging.mutualisation.ca\\\/en\\\/2019\\\/10\\\/25\\\/drug-monitoring-a-quick-look-at-new-drugs-and-new-trends\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/staging.mutualisation.ca\\\/en\\\/2019\\\/10\\\/25\\\/drug-monitoring-a-quick-look-at-new-drugs-and-new-trends\\\/#primaryimage\",\"url\":\"https:\\\/\\\/staging.mutualisation.ca\\\/wp-content\\\/uploads\\\/2016\\\/04\\\/header-2.jpg\",\"contentUrl\":\"https:\\\/\\\/staging.mutualisation.ca\\\/wp-content\\\/uploads\\\/2016\\\/04\\\/header-2.jpg\",\"width\":1920,\"height\":878},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/staging.mutualisation.ca\\\/en\\\/2019\\\/10\\\/25\\\/drug-monitoring-a-quick-look-at-new-drugs-and-new-trends\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/staging.mutualisation.ca\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Drug monitoring: a quick look at new drugs and new trends\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/staging.mutualisation.ca\\\/#website\",\"url\":\"https:\\\/\\\/staging.mutualisation.ca\\\/\",\"name\":\"SOCI\u00c9T\u00c9 DE COMPENSATION EN ASSURANCE M\u00c9DICAMENTS DU QU\u00c9BEC\",\"description\":\"Une entit\u00e9 priv\u00e9e qui rel\u00e8ve de l\u2019industrie des assurances de personnes.\",\"publisher\":{\"@id\":\"https:\\\/\\\/staging.mutualisation.ca\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/staging.mutualisation.ca\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/staging.mutualisation.ca\\\/#organization\",\"name\":\"Soci\u00e9t\u00e9 de compensation en assurance m\u00e9dicaments du Qu\u00e9bec\",\"url\":\"https:\\\/\\\/staging.mutualisation.ca\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/staging.mutualisation.ca\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/staging.mutualisation.ca\\\/wp-content\\\/uploads\\\/2016\\\/07\\\/sticky-icon.png\",\"contentUrl\":\"https:\\\/\\\/staging.mutualisation.ca\\\/wp-content\\\/uploads\\\/2016\\\/07\\\/sticky-icon.png\",\"width\":64,\"height\":55,\"caption\":\"Soci\u00e9t\u00e9 de compensation en assurance m\u00e9dicaments du Qu\u00e9bec\"},\"image\":{\"@id\":\"https:\\\/\\\/staging.mutualisation.ca\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/staging.mutualisation.ca\\\/#\\\/schema\\\/person\\\/16c02f97060cefce556dbfa34014498d\",\"name\":\"Andr\u00e9 Ouellette\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Drug monitoring: a quick look at new drugs and new trends - SOCI\u00c9T\u00c9 DE COMPENSATION EN ASSURANCE M\u00c9DICAMENTS DU QU\u00c9BEC","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/staging.mutualisation.ca\/en\/2019\/10\/25\/drug-monitoring-a-quick-look-at-new-drugs-and-new-trends\/","og_locale":"en_US","og_type":"article","og_title":"Drug monitoring: a quick look at new drugs and new trends - SOCI\u00c9T\u00c9 DE COMPENSATION EN ASSURANCE M\u00c9DICAMENTS DU QU\u00c9BEC","og_description":"The increasing cost of drugs is a constant concern for the Corporation, which ensures that the pooling system continues to protect the viability of plans in case of major claims.","og_url":"https:\/\/staging.mutualisation.ca\/en\/2019\/10\/25\/drug-monitoring-a-quick-look-at-new-drugs-and-new-trends\/","og_site_name":"SOCI\u00c9T\u00c9 DE COMPENSATION EN ASSURANCE M\u00c9DICAMENTS DU QU\u00c9BEC","article_published_time":"2019-10-26T02:00:18+00:00","article_modified_time":"2022-04-27T14:08:32+00:00","og_image":[{"width":1920,"height":878,"url":"https:\/\/staging.mutualisation.ca\/wp-content\/uploads\/2016\/04\/header-2.jpg","type":"image\/jpeg"}],"author":"Andr\u00e9 Ouellette","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Andr\u00e9 Ouellette","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/staging.mutualisation.ca\/en\/2019\/10\/25\/drug-monitoring-a-quick-look-at-new-drugs-and-new-trends\/#article","isPartOf":{"@id":"https:\/\/staging.mutualisation.ca\/en\/2019\/10\/25\/drug-monitoring-a-quick-look-at-new-drugs-and-new-trends\/"},"author":{"name":"Andr\u00e9 Ouellette","@id":"https:\/\/staging.mutualisation.ca\/#\/schema\/person\/16c02f97060cefce556dbfa34014498d"},"headline":"Drug monitoring: a quick look at new drugs and new trends","datePublished":"2019-10-26T02:00:18+00:00","dateModified":"2022-04-27T14:08:32+00:00","mainEntityOfPage":{"@id":"https:\/\/staging.mutualisation.ca\/en\/2019\/10\/25\/drug-monitoring-a-quick-look-at-new-drugs-and-new-trends\/"},"wordCount":640,"publisher":{"@id":"https:\/\/staging.mutualisation.ca\/#organization"},"image":{"@id":"https:\/\/staging.mutualisation.ca\/en\/2019\/10\/25\/drug-monitoring-a-quick-look-at-new-drugs-and-new-trends\/#primaryimage"},"thumbnailUrl":"https:\/\/staging.mutualisation.ca\/wp-content\/uploads\/2016\/04\/header-2.jpg","articleSection":["Archives"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/staging.mutualisation.ca\/en\/2019\/10\/25\/drug-monitoring-a-quick-look-at-new-drugs-and-new-trends\/","url":"https:\/\/staging.mutualisation.ca\/en\/2019\/10\/25\/drug-monitoring-a-quick-look-at-new-drugs-and-new-trends\/","name":"Drug monitoring: a quick look at new drugs and new trends - SOCI\u00c9T\u00c9 DE COMPENSATION EN ASSURANCE M\u00c9DICAMENTS DU QU\u00c9BEC","isPartOf":{"@id":"https:\/\/staging.mutualisation.ca\/#website"},"primaryImageOfPage":{"@id":"https:\/\/staging.mutualisation.ca\/en\/2019\/10\/25\/drug-monitoring-a-quick-look-at-new-drugs-and-new-trends\/#primaryimage"},"image":{"@id":"https:\/\/staging.mutualisation.ca\/en\/2019\/10\/25\/drug-monitoring-a-quick-look-at-new-drugs-and-new-trends\/#primaryimage"},"thumbnailUrl":"https:\/\/staging.mutualisation.ca\/wp-content\/uploads\/2016\/04\/header-2.jpg","datePublished":"2019-10-26T02:00:18+00:00","dateModified":"2022-04-27T14:08:32+00:00","breadcrumb":{"@id":"https:\/\/staging.mutualisation.ca\/en\/2019\/10\/25\/drug-monitoring-a-quick-look-at-new-drugs-and-new-trends\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/staging.mutualisation.ca\/en\/2019\/10\/25\/drug-monitoring-a-quick-look-at-new-drugs-and-new-trends\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/staging.mutualisation.ca\/en\/2019\/10\/25\/drug-monitoring-a-quick-look-at-new-drugs-and-new-trends\/#primaryimage","url":"https:\/\/staging.mutualisation.ca\/wp-content\/uploads\/2016\/04\/header-2.jpg","contentUrl":"https:\/\/staging.mutualisation.ca\/wp-content\/uploads\/2016\/04\/header-2.jpg","width":1920,"height":878},{"@type":"BreadcrumbList","@id":"https:\/\/staging.mutualisation.ca\/en\/2019\/10\/25\/drug-monitoring-a-quick-look-at-new-drugs-and-new-trends\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/staging.mutualisation.ca\/en\/"},{"@type":"ListItem","position":2,"name":"Drug monitoring: a quick look at new drugs and new trends"}]},{"@type":"WebSite","@id":"https:\/\/staging.mutualisation.ca\/#website","url":"https:\/\/staging.mutualisation.ca\/","name":"SOCI\u00c9T\u00c9 DE COMPENSATION EN ASSURANCE M\u00c9DICAMENTS DU QU\u00c9BEC","description":"Une entit\u00e9 priv\u00e9e qui rel\u00e8ve de l\u2019industrie des assurances de personnes.","publisher":{"@id":"https:\/\/staging.mutualisation.ca\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.mutualisation.ca\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/staging.mutualisation.ca\/#organization","name":"Soci\u00e9t\u00e9 de compensation en assurance m\u00e9dicaments du Qu\u00e9bec","url":"https:\/\/staging.mutualisation.ca\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/staging.mutualisation.ca\/#\/schema\/logo\/image\/","url":"https:\/\/staging.mutualisation.ca\/wp-content\/uploads\/2016\/07\/sticky-icon.png","contentUrl":"https:\/\/staging.mutualisation.ca\/wp-content\/uploads\/2016\/07\/sticky-icon.png","width":64,"height":55,"caption":"Soci\u00e9t\u00e9 de compensation en assurance m\u00e9dicaments du Qu\u00e9bec"},"image":{"@id":"https:\/\/staging.mutualisation.ca\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/staging.mutualisation.ca\/#\/schema\/person\/16c02f97060cefce556dbfa34014498d","name":"Andr\u00e9 Ouellette"}]}},"_links":{"self":[{"href":"https:\/\/staging.mutualisation.ca\/en\/wp-json\/wp\/v2\/posts\/8406","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/staging.mutualisation.ca\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/staging.mutualisation.ca\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/staging.mutualisation.ca\/en\/wp-json\/wp\/v2\/users\/22"}],"replies":[{"embeddable":true,"href":"https:\/\/staging.mutualisation.ca\/en\/wp-json\/wp\/v2\/comments?post=8406"}],"version-history":[{"count":5,"href":"https:\/\/staging.mutualisation.ca\/en\/wp-json\/wp\/v2\/posts\/8406\/revisions"}],"predecessor-version":[{"id":20185,"href":"https:\/\/staging.mutualisation.ca\/en\/wp-json\/wp\/v2\/posts\/8406\/revisions\/20185"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/staging.mutualisation.ca\/en\/wp-json\/wp\/v2\/media\/5500"}],"wp:attachment":[{"href":"https:\/\/staging.mutualisation.ca\/en\/wp-json\/wp\/v2\/media?parent=8406"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/staging.mutualisation.ca\/en\/wp-json\/wp\/v2\/categories?post=8406"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/staging.mutualisation.ca\/en\/wp-json\/wp\/v2\/tags?post=8406"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}